natgillin/translations-raw huggingface dataset:
A compound of formula I according to one of claims 1 to 7, wherein W represents N; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 7, naznačen time, da Wpredstavlja N; ili sol takvoga spoja.
A compound of formula I according to one of claims 1 to 7, wherein W represents CH; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 7, naznačen time, da Wpredstavlja CH; ili sol takvoga spoja.
A compound of formula I according to one of claims 1 to 9, wherein Y represents CH; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 9, naznačen time, da Ypredstavlja CH; ili sol takvoga spoja.
A compound of formula I according to one of claims 1 to 9, wherein Y represents N; or a salt of such a compound. 
Spoj formule I prema jednom od zahtjeva 1 do 9, naznačen time, da Ypredstavlja N; ili sol takvoga spoja.
A pharmaceutical composition containing, as active principle, a compound of formula I as defined in one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient. 
Farmaceutski sastav, naznačen time, da kao djelotvorni sastojak sadrži spoj formule I prema jednom od zahtjeva 1 do 13 ili njegovu farmaceutski prihvatljivu sol te najmanje jedno terapeutski inertno pomoćno sredstvo.
is phenyl optionally substituted with one halo substituent; 
je fenil izborno supstituiran sa jednim halo supstituentom;
A compound as claimed in claim 1 selected from: 
Spoj prema patentnom zahtjevu 1 izabran od slijedećih:
A process for the preparation of a compound of general formula (I) as claimed in claim 1, the process comprising reacting a C1-C6 alkyl or benzyl ester of the compound of general formula (I) with a base. 
Postupak za pripremu spoja opće formule (I) prema patentnom zahtjevu 1, naznačen time što taj postupak sadrži reakciju C1-C6 alkil ili benzil estra spoja opće formule (I) sa bazom.
A compound as claimed in any one of claims to 4 for use in the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis and also other PGD2-mediated diseases, for example autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, chronic obstructive pulmonary disease, as well as rheumatoid arthritis, psoriatic arthritis, osteoarthritis and fibrotic diseases caused/exacerbated by Th2 immune responses, for example idiopathic pulmonary fibrosis and hypertrophihic scars. 
Spoj prema bilo kojem od patentnih zahtjeva do 4 za uporabu u liječenju ili prevenciji alergijske astme, nesezonskog alergijskog rinitisa, sezonskog alergijskog rinitisa, atopijskog dermatitisa, kontaktne hipersenzitivnosti (uključujući kontaktni dermatitis), konjuktivitisa, posebno alergijskog konjuktivitisa, proljetnog keratokonjuktivitisa i atopijskog keratokonjuktivitisa, eozinofilnog bronhitisa, alergija na hranu, eozinofilnog gastroenteritisa, inflamatorne bolesti crijeva, ulceroznog kolitisa i Kronove bolesti, mastocitoze i također drugih bolesti posredovanih preko PGD2, na primjer autoimunih bolesti kao što su sindrom hiper IgE i sustavni lupus eritematodes, psorijaza, akne, multipla skleroza, odbacivanje alografta, kronična opstruktivna bolest pluća, kao i reumatoidni artritis, psorijatički artritis, osteoartritis i fibrotičke bolesti uzrokovane/pogoršane preko Th2 imunih odgovora, na primjer idiopatska plućna fibroza i hipertrofični ožiljci.
A composition as claimed in claim 10, wherein the additional active agents are selected from: 
Kompozicija prema patentnom zahtjevu 10, naznačena time što su dodatna aktivna sredstva izabrana od slijedećih:
Suplatast tosylate and similar compounds; 
suplatast tozilat i slični spojevi;
antihistamines, for example histamine H1 receptor antagonists such as loratadine, cetirizine, desloratadine, levocetirizine, fexofenadine, astemizole, azelastine and chlorpheniramine or H4 receptor antagonists; 
antihistamini, na primjer antagonisti histaminskog H1 receptora kao što su loratadin, cetirizin, desloratadin, levocetirizin, feksofenadin, astemizol, azelastin i klorfeniramin ili antagonisti H4 receptora;
anti-IgE antibody therapies such as omalizumab; 
terapije anti-IgE antitijelom kao što je omalizumab;
anti-fungals such as clotrimazole (particularly for the treatment of atopic dermatitis); 
sredstva protiv gljiva kao što je klotrimazol (posebno za liječenje atopijskog dermatitisa);
immunosuppressants such as tacrolimus and particularly pimecrolimus in the case of inflammatory skin disease or alternatively FK-506, rapamycin, cyclosporine, azathioprine or methotrexate; 
imunosupresanti kao što je takrolimus i posebno pimekrolimus u slučaju inflamatorne bolesti kože ili alternativno FK-506, rapamicin, ciklosporin, azatioprin ili metotreksat;
drugs that modulate cytokine production such as inhibitors of TNF converting enzyme (TACE) anti-TNF monoclonal antibodies, TNF receptor immunoglobulin molecules, inhibitors of other TNF isoforms, non-selective COX-1/COX-2 inhibitors such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefanamic acid, indomethacin, sulindac and apazone, pyrazolones such as phenylbutazone, salicilates such as aspirin; COX-2 inhibitors such as meloxicam, celecoxib, fofecoxib, valdecoxib and etoricoxib, low dose methotrexate, lefunomide, ciclesonide, hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold. 
lijekovi koji moduliraju proizvodnju citokina kao što su inhibitori enzima za prevođenje TNFa (TACE), anti-TNF monoklonalna antitijela, TNF receptorne imunoglobulinske molekule, inhibitori drugih TNF izoformi, neselektivni inhibitori COX-1/COX-2 kao što je piroksikam, diklofenak, propionske kiseline kao što je naproksen, flubiprofen, fenoprofen, ketoprofen i ibuprofen, fenamati kao što je mefanaminska kiselina, indometacin, sulindak i apazon, pirazoloni kao što je fenilbutazon, salicilati kao što je aspirin; inhibitori COX-2 kao što je meloksikam, celekoksib, fofekoksib, valdekoksib i etorikoksib, niska doza metrotreksata, lefunomid, ciklesonid, hidroksihlorokvin, d-penicilamin, auranofin ili parenteralno ili oralno zlato;
A compound according to any one of claims 1 to 20, wherein R11 is phenyl, substituted phenyl, tetrahydropyranyl, pyridinyl, alkylpyridinyl, alkylpyridinyl, oxetanyl, pyrrolidinyl, alkylpyrrolidinyl, pyrimidinyl, haloalkylpyrimidinyl, alkylpiperidinyl, pyrazolyl or substituted pyrazolyl, wherein substituted phenyl and substituted pyrazolyl are phenyl and pyrazolyl each substituted with one to three substituents independently selected from halkyl, halogen, alkoxy, alkoxycarbonyl, haloalkoxy, haloalkyl, halophenyl, halopyridinyl, oxodihydropyridinyl and nitro. 
Spoj prema bilo kojem zahtjevu od 1 do 20, naznačen time, da R11 je fenil, supstituirani fenil, tetrahidropiranil, piridinil, alkilpiridinil, alkilpiridinil, oksetanil, pirolidinil, alkilpirolidinil, pirimidinil, haloalkilpirimidinil, alkil-piperidinil, pirazolil ili supstituirani pirazolil, gdje supstituirani fenil i supstituirani pirazolil su fenil i pirazolil svaki supstituiran s jednim do tri supstituenta neovisno odabrana između sljedećih: halkil, halogen, alkoksi, alkoksikarbonil, haloalkoksi, haloalkil, halofenil, halopiridinil, oksodihidropiridinil i nitro.
the reaction of a compound of formula (Ib) in the presence of R1-A-X; or 
reakcija spoja formule (Ib) [image] u prisutnosti R1-A-X; ili
A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 33 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvća spoj prema bilo kojem zahtjevu od 1 do 33 i terapeutski inertan nosač.
A compound of formula (I) according to claim 4 in the form of an amine salt. 
Spoj sa formulom (I) prema zahtjevu 4 naznačen time da je u obliku soli amina.
A salt according to claim 6 in crystalline form which is characterised by an X-ray powder diffraction pattern with peaks at at least one of the following 2-theta values measured using CuKa radiation: 14.6, 17.4 and 21.1. 
Sol prema zahtjevu 6 u kristalnom obliku koja je naznačena time da ima uzorak difrakcije X-zraka na prahu sa vršcima kod barem jedne od slijedećih 2-theta vrijednosti mjereno korištenjem CuKa zračenja: 14.6, 17.4 i 21.1.
A salt according to claim 6 crystalline form which is characterised by an X-ray powder diffraction pattern as shown in Figure 1. 
Sol prema zahtjevu 6 u kristalnom obliku koja je naznačena time da ima uzorak difrakcije X-zraka na prahu kako je prikazano na Slici 1.
A compound according to claim 4 in crystalline form which is characterised by an X-ray powder diffraction pattern as shown in Figure 3. 
Spoj prema zahtjevu 4 u kristalnom obliku koji je naznačen time da ima uzorak difrakcije X-zraka na prahu kako je prikazano na Slici 3.
A compound of formula (1a): 
Spoj naznačen time da ima formulu (1a): [image]
A compound of formula (1c): 
Spoj naznačen time da ima formulu (1c): [image]
A compound of formula (1d): 
Spoj naznačen time da ima formulu (1d): [image]
A compound of formula (1f): 
Spoj naznačen time da ima formulu (1f): [image]
a modulator of chemokine receptor function; 
modulatora funkcije kemokinskog receptora;
a non-steroidal glucocorticoid receptor antagonist. 
ne-steroidni antagonist glukokortikoidnog receptora.
seeding the suspension of ES cells obtained in step b) on a layer of feeder cells and further culturing the ES cells for at least one passage; 
sijanje suspenzije ES stanica dobivenih u koraku b) na sloju hranjivih stanica i daljnji uzgoj kulture ES stanica kroz barem jedan pasaž;
withdrawing IGF-1 and CNTF from the culture medium, and further culturing the cells for at least one passage; 
uklanjanje IGF-1 i CNTF iz medija kulture, i daljnji uzgoj kulture stanice kroz barem jedan pasaž;
progressively decreasing the concentration of feeder cells in the culture medium so as to obtain a total withdrawal of feeder layer after several passages, and further culturing the cells; 
progresivno snižavanje koncentracije hranjivih stanica u mediju kulture tako da se dobije potpuno uklanjanje hranjivog sloja nakon nekoliko pasaža, i daljnji uzgoj kulture stanica;
obtaining adherent continuous diploid avian cell lines derived from ES cells capable of proliferating in a basal medium in the absence of growth factors, and a feeder layer, and wherein said avian cell lines do not produce replication-competent endogenous retrovirus particles. 
dobivanje adherentnih kontinuiranih diploidnih ptičjih staničnih linija iz ES stanica koje su sposobne proliferirati u bazalnom mediju bez prisutnosti faktora rasta i hranjivog sloja, i gdje te ptičje stanične linije ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
The process according to claim 1, wherein after step e) the concentration of animal serum in the culture medium is progressively decreased so as to obtain a total withdrawal of animal serum after several passages. 
Postupak prema zahtjevu 1, gdje se nakon koraka e) koncentracija životinjskog seruma u mediju kulture progresivno smanjuje tako da se dobije potpuno uklanjanje životinjskog seruma nakon nekoliko pasaža.
The process according to claim 7 wherein the egg of said Muscovy duck is incubated to mature before isolating the duck embryo. 
Postupak prema zahtjevu 7 gdje se jaje te mošusne patke inkubira kako bi sazrjelo prije izoliranja pačjeg embrija.
an endogenous telomerase activity; 
aktivnost endogene telomeraze,
a population doubling time of around 30 hours or less at 37°C; 
vrijeme udvostručavanja populacije oko 30 sati ili manje na 37°C;
infecting said avian cells with a virus of interest; 
infekcija tih ptičjih stanica virusom od interesa;
harvest the virus in cell culture supernatant and/or inside said cells. 
uzimanje virusa iz supernatanta stanične kulture i/ili unutrašnjosti tih stanica.
The process according to claim 10, wherein said virus is selected from the group comprising poxviruses, orthomyxoviruses, paramyxoviruses, herpes viruses, hepadnaviruses, adenoviruses, parvoviruses, reoviruses, circoviruses, coronaviruses, flaviviruses, togaviruses, birnavriruses and retroviruses. 
Postupak prema zahtjevu 10, gdje se taj virus izabire iz grupe koja obuhvaća pox viruse, ortomiksoviruse, paramiksoviruse, herpes viruse, hepa dna viruse, adenoviruse, parvoviruses, reoviruse, cirkoviruse, koronaviruse, flaviviruse, togaviruse, birnaviruse i retroviruse.
a poxvirus or a recombinant poxvirus selected among the group comprising Modified Vaccinia Ankara (MVA) virus, Lister-Elstree vaccinia virus, LC16m8 vaccinia virus, CVI78 vaccinia virus, Fowl pox virus, canary pox virus (i.e ALVAC), NYVAC, juncopox virus, mynah pox virus, pigeonpox virus, psittacine pox virus, quail pox virus, sparrow poxvirus, starling pox virus, Turkey pox virus; 
pox virus ili rekombinantni pox virus izabran iz grupe koja obuhvaća Modificirani vakcinija Ankara (MVA) virus, Lister-Elstree vakcinija virus, LC16m8 vakcinija virus, CVI78 vakcinija virus, virus boginja peradi, virus boginja kanarinaca (tj. ALVAC), NYVAC, virus boginja ptice junko, virus boginja ptice mina, virus boginja goluba, virus boginja papiga, virus boginja prepelica, virus boginja vrabaca, virus boginja čvorka, virus boginja purana;
a paramyxovirus or a recombinant paramyxovirus selected among the group comprising measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human para-influenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, duck para-influenza virus; 
paramiksovirus ili rekombinantni paramiksovirus izabran iz grupe koja obuhvaća virus ospica, virus zaušnjaka, rubela virus, Sendai virus, Respiratorni Sincicijski virus (RSV), humani para-influenca tipovi I i III, virus goveđe kuge, virus pseće kuge, virus Newcastle bolesti, virus pačje para-influence;
an orthomyxovirus, a recombinant orthomyxovirus or a reassorted orthomyxovirus selected among human influenza virus, avian influenza virus, swine influenza virus, equine influenza virus, feline influenza virus; 
ortomiksovirus, rekombinantni ortomiksovirus ili reasortirani orthomiksovirus izabran između virusa ljudske gripe, virusa ptičje gripe, virusa svinjske gripe, virusa konjske gripe, virusa mačje gripe;
a togavirus preferably selected among Sinbis virus, Semliki forest virus, O'nyong'nyong virus,Chikungunya virus, Mayaro virus, Ross river virus, Eastern equine encephalitis virus, Western Equine encephalitis virus, Venezuelan Equine encephalitis virus, or a recombinant togavirus thereof; 
togavirus poželjno izabran između Sindbis virusa, virusa Semliki šume, O’nyong’nyong virusa, Chikungunya virusa, Mayaro virusa, virusa rijeke Ross, virus istočnog konjskog encefalitisa, virus zapadnog konjskog encefalitisa, virus venecuelanskog konjskog encefalitisa, ili njihov rekombinantni togavirus;
an adenovirus selected among fowl adenovirus, goose adenovirus, duck adenovirus and pigeon adenovirus or a recombinant adenovirus thereof; 
adenovirus izabran između adenovirusa peradi, adenovirusa guske, pačjeg adenovirusa i golubljeg adenovirusa ili njihovog rekombinantnog adenovirusa;
a flavivirus preferably selected among Dengue virus, Japanese encephalitis virus and West Nile virus. 
flavivirus poželjno izabran između Dengue virusa, virusa japanskog encefalitisa i virusa zapadnog Nila.
genetically modifying the continuous diploid avian cell lines obtained by the process according to any one of claims 1 to 9, by transient or stable transfection of an expression vector; 
genetičko modificiranje kontinuiranih diploidnih ptičjih staničnih linija dobivenih u postupku prema bilo kojem od zahtjeva 1 do 9, prijelaznom ili stabilnom transfekcijom vektora ekspresije;
The compound of claim 1 that is a compound of formula 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule [image] .
The composition of claim 15 further comprising at least one additional anti-diabetic agent. 
Pripravak u skladu s patentnim zahtjevom 15, naznačen time što dodatno sadrži najmanje jedno dodatno antidijabetično sredstvo.
The compound of any one of claims 1 to 14, or the composition of any one of claims 15 to 17, for use in treating or delaying the progression or onset of Type 2 diabetes. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time što su namijenjeni upotrebi u liječenju ili odgađanju napredovanja ili početka dijabetesa tip 2.
The compound of any one of claims 1 to 14, or the composition of any one of claims 15 to 17, for use in treating nonalcoholic fatty liver disease (NAFLD) or hepatic insulin resistance. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time što su namijenjeni upotrebi u liječenju nealkoholne bolesti masne jetre (NAFLD) ili jetrene otpornosti na inzulin.
Bethanechol for use according to claim 1, wherein the xerostomia is associated with head and neck cancer. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s rakom glave i vrata.
Bethanechol for use according to claim 1, wherein the xerostomia is associated with drug treatment. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s uporabom lijekova.
Bethanechol for use according to claim 1, wherein the xerostomia is associated with cancer chemotherapy treatment. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s kemoterapijskim liječenjem raka.
Bethanechol for use according to claim 1, wherein the xerostomia is associated with Sjogren's syndrome. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana sa Sjogrenovim sindromom.
Bethanechol for use according to claim 1, wherein the xerostomia is associated with late-stage cancer. 
Betanekol za uporabu prema zahtjevu 1, pri čemu je kserostomija povezana s rakom u kasnoj fazi.
A microfluidic device according to claim 1, wherein said nanostructured metal oxide is constituted by nanoparticles with a size distribution covering the range from about 2 to about 50 nm and centered within 5 and 15 nm. 
Mikrofluidni uređaj prema zahtjevu 1, gdje je nano-strukturirani metalni oksid sastavljen od nanočestica s raspodjelom veličine koja obuhvaća raspon od oko 2 do oko 50 nm, sa središnjim dijelom raspona unutar 5 i 15 nm.
A microfluidic device according to claim 1 wherein the nanostructured metal oxide has a porous structure with a mass density from about 1/2 to about 1/10, of the mass density of the corresponding bulk oxide. 
Mikrofluidni uređaj prema zahtjevu 1, gdje nano-strukturirani metalni oksid ima poroznu strukturu s masenom gustoćom od oko 1/2 do oko 1/10 masene gustoće odgovarajućeg oksida na veliko (bulk).
leaving the cells incubating; 
ostavljanje stanica da se inkubiraju;
fixing the cells with a solution of an alcohol and a weak carboxylic acid; 
fiksiranje stanica otopinom alkohola i slabe karboksilne kiseline;
adding a solution of a denaturing agent; 
dodavanje otopine sredstva za denaturaciju;
repeating step g) once; adding the labelled probe and leaving incubating; 
jedno ponavljanje koraka g); dodavanje označene probe i ostavljanje da se inkubira;
washing with a solution comprising SSC and NP40, wherein the cell sample is in the form of a cell suspension. 
pranje otopinom koja sadrži SSC i NP40, pri čemu je stanični uzorak u obliku stanične suspenzije.
Use according to claim 11, wherein said cell suspension is a suspension of non-adhering cells. 
Uporaba prema zahtjevu 11, gdje je suspenzija stanica suspenzija ne-prijanjajućih stanica.
Use according to claim 12, wherein said non-adhering cells are living cells. 
Uporaba prema zahtjevu 12, gdje su te ne-prijanjajuće stanice žive stanice.
The coupling according to claim 1, characterized in that said engagement means is constituted by a partial thread (2). 
Spoj prema zahtjevu 1, naznačen time što je sredstvo za zahvaćanje napravljeno kao djelomični navoj (2).
The coupling according to one or more of the preceding claims, characterized in that said centering shank (7) is hollow and comprises an internal thread which is suitable to engage a threaded pin (12) which is rigidly associated with said stock (14). 
Spoj prema jednom ili više od prethodnih zahtjeva, naznačen time što je centrirajući krak (7) šupalj i obuhvaća unutarnji navoj koji je prikladan za spajanje s navojnom iglom (12) koja je čvrsto povezana s okvirom (14).
The coupling according to one or more of the preceding claims, characterized in that said main body (1) is associated with said stock (14) by means of a centering member (15) which is rigidly coupled to said stock (14). 
Spoj prema jednom ili više od prethodnih zahtjeva, naznačen time što je glavno tijelo (1) povezano s okvirom (14) preko centrirajućeg člana (15) koji je čvrsto spojen za taj okvir (14).
A foam layer (6) according to claim 3, characterised in that the lines (13) lines have an equal distance from each other. 
Sloj pjene (6) prema zahtjevu 3, naznačen time da linije (13) imaju jednaku međusobnu udaljenost.
A foam spring (1) according to any of claims 10 to 12, characterised in that the holes (3) are mainly diamond-shaped. 
Pjenaste opruge (1) prema zahtjevu 10 ili 11, naznačene time da su otvori (3) uglavnom oblika dijamanta.
A method for increasing resistance to citrus canker disease in a plant or cell, comprising overexpressing the nucleotide sequence set forth in SEQ ID NO: 1. 
Postupak za povećanje otpornosti na bolest raka citrusa u biljci ili stanici, naznačen time da se sastoji od prekomjernog eksprimiranja nukleotidne sekvence prikazane u SEQ ID NO: 1.
A method for increasing resistance to citrus canker disease in a plant or cell, comprising 
Postupak za povećanje otpornosti na bolest raka citrusa u biljci ili stanici, naznačen time da se sastoji od
regenerating a plant from said transformed plant or cell; 
regeneriranja biljke iz navedene transformirane biljke ili stanice;
selecting a plant or cell that has increased resistance to citrus canker disease relative to a control plant. 
odabira biljke ili stanice koja ima povećanu otpornost na bolest raka citrusa u odnosu na kontrolnu biljku.
The method of claim 9, wherein said planet is selected from the genera, of Citrus, Poncirus, Fortunella, Murraya, Microcitrus, Limonia, and Eremocitrus. 
Postupak prema zahtjevu 9, naznačen time da je navedena biljka odabrana iz roda Citrus, Poncirus, Fortunella, Murraya, Microcitrus, Limonia, i Eremocitrus.
A transgenic plant or a progeny, fruit, or seed thereof, said plant, progeny, fruit or seed having incorporated into its genome 
Transgena biljka ili njeno potomstvo, voće, ili sjeme, navedena biljka, potomstvo, voće ili sjeme naznačena time da ima u svojem genomu uključuje
a promoter that functions in plants and that is operatively linked to the nucleotide sequence, wherein said plant overexpresses the disease resistance polypeptide. 
promotor koji djeluje u biljkama i koji je operativno povezan na nukleotidnu sekvencu, pri čemu navedena biljka prekomjerno eksprimira polipeptid otporan na bolest.
The transgenic plant of claim 11, wherein the nucleotide sequence is the one set forth in SEQ ID NO: 1. 
Transgena biljka prema zahtjevu 11, naznačena time da je nukleotidna sekvenca jedna koja je prikazana u SEQ ID NO: 1.
The transgenic plant of claim 11, having further incorporated into its genome (iii) an enhancer sequence that is fused to the promoter. 
Transgena biljka prema zahtjevu 11, naznačena time da dodatno ima u svoj genom uključenu (iii) sekvencu pojačivača koja je kondenzirana na promotor.
imiquimod, having the specific formula 1-isobutyl-1 H -imidazo[4,5- c]quinolin-4-amine, selected from following formula (X): 
imikimod, koji ima specifičnu formulu 1-izobutil-1H-imidazo[4,5-c]kinolin-4-amin, koji je odabran iz slijedeće formule (X): [image] .